Skip to main content

Table 4 Analysis using a Cox proportional hazard model to verify the prognostic factor associated with survival in the chemotherapy group (N = 31)

From: Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

  Hazard ratio 95% confidence interval p-value
Univariate analysis
 Age 0.995 0.884–1.12 0.929
 ECOG Performance status = 2 0.994 0.453–2.18 0.987
 Brinkman Index 0.999 0.998–1.00 0.104
 Emphysema 0.649 0.241–1.74 0.391
 Diabetes mellitus 0.990 0.448–2.189 0.980
 Squamous cell carcinoma 1.15 0.420–3.12 0.792
 Major diameter of the primary site 1.02 0.997–1.03 0.102
 Brain metastasis 2.82 0.986–8.04 0.0533
 Bone metastasis 3.07 1.24–7.57 0.0150
 Liver metastasis 1.29 0.294–5.65 0.736
 Adrenal gland metastasis 4.77 1.21–18.8 0.0253
 Carboplatin-based doublet therapy 1.12 0.513–2.46 0.773
 Number of treatment cycles 0.665 0.483–0.915 0.0122
 Lymphocyte count 1.00 0.999–1.00 0.321
 Hemoglobin 0.789 0.621–1.00 0.0511
 Albumin 0.180 0.0694–0.465 0.000408
 Lactate dehydrogenase 1.00 0.998–1.00 0.455
 Calcium 1.15 0.764–1.72 0.51
 C-reactive protein 1.08 0.961–1.21 0.196
Multivariate analysis
 Bone metastasis 1.98 0.666–5.90 0.2190
 Adrenal gland metastasis 2.19 0.470–10.17 0.3180
 Number of treatment cycles 0.744 0.518–1.07 0.110
 Albumin 0.18 0.0638–0.508 0.00121
  1. In the univariate analysis, serum albumin level, number of cycles, the existence of bone metastasis, and the existence of adrenal gland metastasis, all with p-values <0.05, were selected as candidate factors. A multivariate analysis identified serum albumin level as an independent factor associated with survival
  2. Abbreviations: ECOG Eastern Cooperative Oncology Group